Lisa Lee, M.D.

877-541-4673
Lisa Lee, M.D.
Hematologist
Clinical Expertise
  • Amyloidosis
  • Complex Multiple Myeloma
  • Multiple Myeloma
  • Smoldering Myeloma
  • Hematopoietic cell transplantation HCT
  • CAR T-cell therapy
Other Languages Spoken
Mandarin
Academic Appointments

Associate Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Myeloma and Multiple Myeloma

Lisa Lee, M.D., is an Associate Clinical Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope. Dr. Lee's journey into medicine began with an interest in biology research during college, which evolved into a desire to see how science could directly help people. She chose oncology due to its research-driven nature and the potential to make significant impacts on patient care.

Dr. Lee is particularly excited about the advancements in precision medicine and the understanding of how the immune system can be harnessed to fight cancer effectively. She was drawn to City of Hope because of its research energy and patient-centered focus, and she believes that the state-of-the-art, cutting-edge research at City of Hope sets it apart from other institutions.

Her philosophy when working with patients is to understand their perspectives and wishes, and she is continually inspired by the resilience and strength of her patients. Dr. Lee wants every patient who walks into City of Hope to feel that they are going to receive the best care possible. To her, hope means feeling powerful and in charge of one's destiny in the face of serious illness.

Outside of work, Dr. Lee enjoys yoga, hiking, and being outdoors. She speaks Mandarin fluently.

Location

Education & Experience

Degrees

  • Medical Degree, 2012, Robert Wood Johnson Medical School — New Brunswick, NJ
  • Bachelor of Arts in Cell Biology/Neuroscience, Bachelor of Arts in Statistics, 2008, Rutgers University — New Brunswick, NJ

Fellowship

  • Fellowship in Hematology/Oncology, 2015-2018, Tufts Medical Center — Boston, MA

Residency

  • Residency in Internal Medicine, 2013-2015, Montefiore Medical Center — Bronx, NY

Internship

  • Internship in Internal Medicine, 2012-2013, Montefiore Medical Center — Bronx, NY

Professional Experience

  • Associate Clinical Professor, 2025-Present, City of Hope Orange County — Irvine, CA
  • HS Assistant Clinical Professor, 2018-2025, University of California Irvine — Orange, CA

Awards & Memberships

Awards

  • 2021, UCISOM Physician Scientist Training Program Awardee
  • 2019, Department of Medicine Chair’s Education Faculty Development and Curricular Innovation Grant
  • 2017, Amyloidosis Foundation Young Investigator’s Award
  • 2004-2008, Dean’s Award for Academic Excellence; Rutgers College
  • 2007, Egbert Le Favre Scholarship for Premedical or Biological Science
  • 2003- 2004, Edward J. Bloustein Distinguished Scholar Award

Memberships

  • UCI IRB Biomedical Committee Member
  • Fellowship Program Evaluation Committee
  • Fellowship Clinical Competency Committee
  • Multiple Myeloma Committee, University of California
  • Hematologic Malignancies Consortium
  • Medical Oncology Association of Southern California
  • Associate Member, American Society of Hematology

Publications

  • Leitao Jr MM, Han G, Lee LX, Abu-Rustum NR, Brown CL, Chi DS, Sonoda Y, Levine DA, Gardner GJ, Jewell EE, Barakat RR. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. American journal of obstetrics and gynecology. 2010 Oct 1;203(4):349-e1.
  • Lee LX, et al. "Plasmablastic lymphoma: a case series of the changing epidemiology of a rare extramedullary plasmacytoid neoplasm, diagnostic challenges, and therapeutic implications." Blood 124.21 (2014): 2995-2995. Blood 124.15 (2014): 2354-2361
  • Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. Journal of hematology & oncology 7.1 (2014): 58.
  • Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 9;124(15):2354-61.
  • Wong, Sandy W., et al. "Primary amyloidosis with renal involvement: outcomes in 77 consecutive patients at a single center." Clinical Lymphoma Myeloma and Leukemia 17.11 (2017): 759-766.
  • Lee LX, Siraj A, Genega E, Reed D, Sokol E, Mathew P. Aggressive-variant microsatellite stable POLE mutant prostate cancer with high mutation burden and durable response to immune checkpoint inhibitor therapy. JCO Precision Oncology 2 (2018): 1-8
  • Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D, Warner M, Miller KB, Lee LX, Varga C, Comenzo RL. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Experimental hematology & oncology. 2018 Dec;7(1):27.
  • Fu J, Lee LX, Zhou P, Fogaren T, Varga C, Comenzo RL. A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. The American journal of case reports (2019) 20:43
  • Lee LX, Zhou P, Varga C, Fogaren T, Ho K, Ma X, Warner M, Toskic D, Kugelmass A. Comenzo RL. Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms. Amyloid 26:2 (2019): 101-102
  • Ma X, Zhou P, Kugelmass A, Toskic D, Warner M, Lee LX, Fogaren T, Godara A, Wang M, Li Y, Yang L. A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases. Gene therapy. 2019 May;26(5):187-97.
  • Godara A, Siddiqui NS, Lee LX, Toskic D, Fogaren T, Varga C, Comenzo RL. Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement. Clinical Lymphoma Myeloma and Leukemia, (2020) 20(3), 184-189.
  • Lee LX, and Shengwen Calvin Li. "Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective." World Journal of Stem Cells 12.8 (2020): 706.
  • Nguyen L, Souccar S, Zuckerman JE, Chen JLT, Katrivesis J, Abi-Jaoudeh N, Lee LX, Reddy U, Baraghoush A, Morrison DE, Li X, Wang B, Lau WL. Kidney biopsy: Challenges with peri-procedural management. J Nephropathol. 2021;10(x):exx. DOI: 10.34172/jnp.2021.xx.
  • Rosenberg, A., Muñoz, M., Costello, C., Brem, E., Reid, E., Maverakis, E., Kaesberg, P., Lee LX, Tuscano, J. and Abedi, M., 2021. P-215: A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma and Leukemia, 21, pp.S157-S158.
  • Scalia, S., Toskic, D., Zhou, P., Mansukhani, M.M., Lee LX, Wong, S.W., Tuchman, S.A., Hoffman, J.E., Fogaren, T., Varga, C. and Lentzsch, S., 2022. The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients. Blood, 140(Supplement 1), pp.10120-10121.
  • Ping Zhou, Mahesh M Mansukhani, Denis Toskic, Stephanie Scalia, Lee LX, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo; Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM). Blood 2022; 140 (Supplement 1): 10048–10049.
  • Tran, M. H., Lee LX, Cao, Y., Vu, L., & Pakbaz, Z. (2023). Caplacizumab as rescue therapy in refractory TTP involving neurologic features. Transfusion and Apheresis Science, 62(3), 103656.